Browsing Tag
KalVista Pharmaceuticals
2 posts
Investors eye KalVista’s $125m debt raise—Can EKTERLY commercialization justify the premium terms?
KalVista raises $125M through convertible notes due 2031 to fund EKTERLY commercialization. Find out what this financing means for biotech investors.
KalVista Pharmaceuticals wins EU and Swiss approval for EKTERLY—what does this mean for the stock?
KalVista Pharmaceuticals secures EU and Swiss approval for EKTERLY, the first oral HAE therapy. Can this rare disease breakthrough lift KALV stock?